Celsion (CLSN) Upgraded by Zacks Investment Research to Hold

Share on StockTwits

Celsion (NASDAQ:CLSN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Shares of CLSN traded up $0.01 during trading hours on Friday, reaching $2.85. The stock had a trading volume of 114,800 shares, compared to its average volume of 270,347. Celsion has a 12 month low of $1.26 and a 12 month high of $6.06. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.48. The stock has a market cap of $49.16 million, a P/E ratio of -1.19 and a beta of 1.14.

Celsion (NASDAQ:CLSN) last issued its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Celsion had a negative return on equity of 109.99% and a negative net margin of 4,479.42%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. analysts expect that Celsion will post -1.56 EPS for the current year.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 369,860 shares of the biotechnology company’s stock, valued at approximately $828,000. Sabby Management LLC owned about 2.08% of Celsion at the end of the most recent quarter. 4.82% of the stock is owned by hedge funds and other institutional investors.

Celsion Company Profile

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply